New injection for Graves' disease enters first human tests

NCT ID NCT07286656

Recruiting now Disease control Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a single injection of a new drug called GenSci098 in 24 adults with Graves' disease, a condition where the thyroid is overactive. The main goal is to check safety and side effects over about 5 months. Researchers will also measure how the drug moves through the body. This is a first step to see if GenSci098 might help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GenSci098
What this could lead to: If safe and effective, GenSci098 could offer a new treatment option for Graves' disease, potentially reducing the need for long-term medication.
What could go wrong: This is a very early Phase 1 trial with only 24 people, focused on safety. It is too soon to know if it works, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENSCI098 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Graves disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENSCI098 GRAVES DISEASE SAFETY TOLERABILITY

Contacts and locations

Locations

The First Affiliated Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, 110801, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.